Table 4.
Effect of baseline characteristics on survival measures in patients with de novo del(17p) (n = 310)
| Independent variable | Progression-free survival (PFS) | Overall survival (OS) | ||||
|---|---|---|---|---|---|---|
| p-value for univariable analysis | HR (95% CI) for multivariable analysis | p-value for multivariable analysis | p-value for univariable analysis | HR (95% CI) for multivariable analysis | p-value for multivariable analysis | |
| Age ≥65 vs. <65 years (147 vs. 163) | 0.714 | NI | – | 0.010 | 1.40 (0.96–2.04) | 0.079 |
| Creatinine >2 vs. ≤2 mg/dL (52 vs. 231) | 0.027 | 1.18 (0.66–2.00) | 0.561 | 0.072 | 0.86 (0.49–1.47) | 0.600 |
| Bone marrow PCs ≥50% vs. <50% (164 vs. 140) | 0.110 | NI | – | 0.536 | NI | – |
| ISS III vs. I/II stage (93 vs. 154) | <0.001 | 1.89 (1.31–2.71) | <0.001 | <0.001 | 2.08 (1.42–3.04) | <0.001 |
| Elevated vs. normal LDH (49 vs. 157) | 0.001 | 1.72 (1.13–2.53) | 0.012 | 0.003 | 1.83 (1.16–2.80) | 0.009 |
| High-risk translocation vs. no high-risk translocation (75 vs. 235) | 0.001 | 1.61 (1.10–2.32) | 0.015 | <0.001 | 1.53 (1.01–2.27) | 0.044 |
| Monosomy 13 vs. no monosomy 13 (163 vs. 147) | 0.020 | 1.08 (0.75–1.57) | 0.672 | 0.024 | 1.04 (0.63–1.72) | 0.885 |
| HRD vs. no HRD (112 vs. 198) | <0.001 | 0.88 (0.54–1.42) | 0.614 | 0.038 | 0.79 (0.52–1.20) | 0.277 |
| High PC proliferative rate vs. low proliferative rate (42 vs. 98) | <0.001 | 1.56 (0.93–2.60) | 0.090 | 0.042 | 0.92 (0.52–1.63) | 0.788 |
| PI-containing induction vs other induction therapy (219 vs. 89) | 0.935 | NI | – | 0.472 | NI | – |
| Diagnosis upto 2012 vs. later (173 vs. 137) | <0.001 | 0.52 (0.36–0.75) | <0.001 | 0.011 | 0.76 (0.47–1.19) | 0.236 |
| Percentage of PCs with del(17p) | ||||||
| ≥20% vs. <20% (224 vs. 36) | 0.074 | 1.85 (0.96–4.13) | 0.068 | <0.001 | 1.07 (0.38–4.46) | 0.916 |
| ≥30% vs. <30% (207 vs. 53) | 0.057 | 1.91 (1.12–3.50) | 0.015 | <0.001 | 1.36 (0.65–3.34) | 0.441 |
| ≥40% vs. <40% (193 vs. 67) | 0.012 | 1.85 (1.15–3.12) | 0.009 | 0.001 | 1.17 (0.60–2.49) | 0.662 |
| ≥50% vs. <50% (170 vs. 90) | 0.025 | 1.45 (0.96–2.26) | 0.079 | 0.011 | 1.09 (0.62–2.03) | 0.769 |
| ≥60% vs. <60% (153 vs. 107) | 0.050 | 1.28 (0.89–1.88) | 0.184 | <0.001 | 1.18 (0.67–2.11) | 0.570 |
The final multivariable model included 174 patients for PFS and 191 patients for OS for whom the parameters were available
Hyperdiploidy was defined as presence of trisomy involving ≥2 odd numbered chromosomes; the results were similar when presence of any trisomy/tetrasomy was used instead of HRD
HR hazard ratio, HRD hyperdiploidy, ISS international staging system, LDH lactate dehydrogenase, NI not included in analysis, PC plasma cell, and PI proteasome inhibitor.
The values given in bold represent P-values <0.05, which are considered statistically significant